Madrigal’s and Viking’s NASH Drugs: Who’s best in class?

Title: Madrigal’s and Viking’s NASH Drugs: Who’s best in class? Author: Peter G. Traber, MD Two companies, Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX), this year...
Learn More

NASH Bubble?

Title: NASH Bubble? Author: Peter G. Traber, MD Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) have been the subject of intense interest in the biotech/pharma...
Learn More

Identifying Best Disease Indications for Anti-Fibrotic Drugs

Identifying Best Disease Indications for Anti-Fibrotic Drugs By Peter G. Traber, MD
Learn More

mRNA vaccines: ready for prime time?

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Senolytics- taking aim at ageing cells

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Drugs and the human gut microbiome – beyond antibiotics

by Saadia Basharat, PhD, Consultant and Ashley Clark, Consultant Intern at Alacrita
Learn More

How to start a biotech company

How to start a biotech company by Rob Johnson, Managing Partner and Jess Hearn, Consultant, at Alacrita
Learn More

Why is it so daunting for US biotech and pharma to launch drugs in Europe themselves?

by Anna Casse, Managing Partner and Saadia Basharat, Consultant, at Alacrita
Learn More

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies?

by Saadia Basharat, PhD, Consultant, Alacrita  
Learn More

What’s the difference between biotech and pharma? 

What’s the difference between biotech and pharma?  How are biotechnology drugs different from traditional pharmaceuticals, and how are biotech companies different to pharma companies?
Learn More

Brexit: What are the options for UK registered MAHs?

By Saadia Basharat, PhD, Consultant
Learn More

European Biotech - Gaining weight and learning patience

European biotech has always been at an investment disadvantage relative to US biotech and this is reflected by the continuing lead in the USA on all financial parameters. This is not a result of...
Learn More